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DISEASE MANAGEMENT
Volume 4, Number 1, 2001
Mary Ann Liebert, Inc.
Chief Medical Officers’ Perceptions of 
Disease Management Programs
GANG XU, Ph.D.1, LISA E. PADDOCK, M.P.H.1, JOHN P. O’CONNOR, Ph.D.1, 
DAVID B. NASH, M.D., M.B.A.,1 and MARK ZITTER2
ABSTRACT
The purpose of this article is to examine chief medical officers’ (CMOs) perception of disease
management programs. Five open-ended questions, each addressing a major issue in the de-
velopment of disease management programs, were given to 31 CMOs who attended a series
of invitation-only conferences on disease management in the fall of 1999. Qualitative data
analysis was conducted using the transcripts on each of the issues. Overall, the CMOs viewed
the emergence of capitated disease management programs positively. They considered the
population of a program to be the contractual patients and/or those at risk for the target dis-
ease. On the issue of quality and cost, they preferred an optimal balance between the two.
They saw the Internet as an opportunity for the education of patients as well as providers.
However, they were concerned about patient confidentiality and further widening of the gap
between those who have the financial means to access healthcare and those who do not. In
spite of concerns expressed about the current generation of disease management programs,
the CMOs held an optimistic view of the future of these programs. To become better accepted,
disease management programs must address the issues of confidentiality and quality of care.
19
ACCOMPANYING THE HISTORICAL CHANGE froman “industrial model of medicine” to an
“information model” is the emergence of dis-
ease management (DM).1 DM is a mechanism
to coordinate medical resources for patients
across the entire healthcare delivery system.2
The main features of DM include a com-
prehensive focus on a particular disease, 
population-oriented health and medical care,
emphasis on evidence-based medicine and
demonstrated best practices, mechanisms to
connect treatment and information across care
settings, cost containment, and outcome as-
sessment.3 DM emphasizes preventive care for
all members of a plan. Primarily, DM is inte-
grated into the healthcare system by educating
patients and providers. As DM evolves, the In-
ternet is being used more frequently as a means
of patient and provider education.3 The chief
medical officer (CMO), a role just now being
defined, often acts as the advocate and portal
for DM to managed care organizations, hospi-
tals, and healthcare systems.
Presently, in the United States there are two
main provider organization reimbursement
methods: full-risk sharing (capitation [CP]) and
1Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, Pennsylvania.
2The Zitter Group, Oakland, California.
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fragmental contractual payment (fee for service
[FFS]). CP refers to a specific amount of money
that is received for a set of services.4 FFS, on
the other hand, refers to monies received for
every service provided. The percentage of
health maintenance organizations using CP
and FFS reimbursement for primary care and
specialty care physicians has risen drastically
from 1993 to 1998.5 CP has not grown as
quickly for hospitals and systems because as-
suming full risk for patients increases the
chance of economic loss.6 Widespread concern
among both payers and providers about the
risks of the CP approach raises doubts about
its long-term feasibility.
Other issues of major concern are quality and
cost of care. Historically, DM programs were
initiated to provide quality care that is cost ef-
fective.3,7,8 However, some DM programs have
focused only on reduced costs and have not im-
proved care.9 This raises concern about the real
purpose of DM programs.7
DM obviously poses many challenges for
providers and organizations, and particularly
for decision makers. For instance, how to de-
fine a DM population remains problematic. As
more DM programs arise for various disease
states, defining the target population becomes
even more difficult. To be cost effective, a pro-
gram must be targeted to the appropriate mem-
bers. Other issues that plague decision makers
involve information technology and patient
privacy.
These are important and urgent questions
facing the current generation of DM programs.
We presented these questions to a group of
CMOs in the United States. Through both for-
mal and interactive sessions, common themes
emerged from their responses to each question.
The purpose of this article is to examine how
CMOs’ perceptions can shed light on the fur-
ther evolution of DM.
METHODS
Participants
The study was conducted at the Second Na-
tional Conference of the Society of Chief Med-
ical Officers (Solution Series Workshop) during
the fall of 1999. Forty-one attending CMOs
served as participants in the study. The con-
ferences were held in three locations: San Fran-
cisco, Chicago, and Washington, DC. The re-
spective numbers of CMOs in each location
were 15, 18, and 8. The participants represented
a broad array of health systems, hospitals,
physician organizations, and health plans.
Instrument
Questions directly relevant to the develop-
ment and implementation of DM programs
were initially developed based on informal dis-
cussion and literature review. Three physicians
from Thomas Jefferson University Hospital,
CareWise Inc., and Evanston Northwestern
Healthcare reviewed the questions for the im-
portance of the issues. A survey consisted of
five open-ended questions relating to compar-
isons between reimbursement types, definition
of the program population, role of non-physi-
cian leadership, information access, and confi-
dentiality. The questions were presented to the
participants during an interactive discussion
session at each conference location. These five
questions were:
1. What is the impact of full risk sharing (cap-
itation—CP) versus fragmented contractual
payment (fee for service—FFS) on disease
management?
2. What is the best definition of a population
in disease management?
3. How do the non-physician leadership and
the drive for a positive Return on Invest-
ment (ROI) affect the development and im-
plementation of disease management pro-
grams?
4. What do you see as the impact of the Inter-
net and unfettered access to health informa-
tion on disease management programs and
the role of the physician?
5. What are some of the concerns regarding pa-
tient confidentiality that will affect disease
management programs?
Procedure, data collection, and analysis
Each participant was asked to write their an-
swers to these five questions presented to them
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during a discussion session. There was no time
limit on the completion of the questions. Each
participant worked independently while an-
swering the questions.
Qualitative analysis10 was performed to
group the data into major categories. The pro-
cedure consisted of three steps. In the first step,
two of the authors reviewed the detailed tran-
scripts, and themes were derived from the re-
sponses to each question. In the second step,
reviewers analyzed the themes, and a general
theme from each question was extracted. This
theme is then illustrated in detail, using direct
quotations. In the third step, story-like sum-
mary responses for each question were devel-
oped. The final results were based on these
themes and summarized in a descriptive for-
mat.
RESULTS
The themes derived for each question were
compared across the three locations. Because
similar themes were derived at each location,
the results are reported combining the data
from the three locations. The findings are pre-
sented in the same sequence they were asked.
1. What is the impact of full risk sharing (cap-
itation—CP) versus fragmented contractual
payment (fee for service—FFS) on disease
management?
An overwhelming majority of the CMOs felt
that CP is superior to FFS in terms of DM. CP
is a “a much greater driver for implementation
of disease management programs” and it
“aligns the incentives in a way that would fa-
cilitate development of DM.”
Specifically, the advantages cited by the
CMOs favoring CP consist of management, in-
centives, and ownership, as noted below:
“FFS may cause unintended conflicts.”
“CP is more likely to induce physician co-
operation through alignment of finan-
cial incentives.”
“FFS seems doomed to fail [because] the
physicians have no ownership.”
Although the CMOs agreed that CP might
have a potentially higher risk than FFS, the risk
taken by CP was seen positively:
“The greater the risk, the greater the in-
centive to have effective disease mange-
ment programs.”
“Full risk increases the success of imple-
mentation.”
2. What is the best definition of a population
in DM?
Although the definitions of a population in DM
varied among the CMOs, most tended to de-
fine it based on two components: the disease
state and the financially contracted member-
ship. In reference to disease state, the CMOs
described the DM population as:
“A distinct group who have a defined and
recognized cluster of symptoms or a dis-
ease.”
“Those with the disease and those who
have potential to develop the disease.”
“The population of present and future per-
sons at risk of illness.”
In reference to the financially contracted
membership, the CMOs described the DM pop-
ulation as:
“The entire enrolled membership.”
“. . . the risk population financially con-
tracted . . .”
“Contractual population with a disease
state, diagnosed or at risk for disease
state.”
3. How do the non-physician leadership and the
drive for a positive Return on Investment
(ROI) affect the development and implemen-
tation of disease management programs?
The reactions to the non-physicians’ leadership
role in DM were mixed. However, most CMOs
commented that non-physician leadership was
seen hand in hand with a focus on positive ROI.
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To support the need for non-physician lead-
ership, some CMOs agreed that a positive ROI
“drives everything” and is “the bottom line.”
Similar viewpoints were expressed, such as:
“No margin, no mission . . .”
“It will eliminate ineffective programs . . .”
On the other hand, a majority of the CMOs
said that DM programs run by non-physician
leaders would become like business enter-
prises where the bottom line was the key dri-
ving force. Therefore, CMOs feared that the
optimal balance between cost and quality in
such DM programs would not be achievable.
According to some CMOs, “Non-physician
leadership focuses on short-term returns
whereas DM return is long-term.” The CMOs
also perceived that there might be a bias to-
ward selecting certain types of diseases for
management if cost becomes the highest pri-
ority. If achieving a positive ROI becomes the
sole criterion for implementation of a DM pro-
gram, there could be unfortunate conse-
quences. Thus, some CMOs responded rather
negatively:
“Non-physician decision makers and the
demand for an ROI may inhibit the de-
velopment and implementation of the
program.”
“There would be a bias for selecting dis-
eases . . . as opposed to a pure med-
ical/public health model of what the
population needs.”
4. What do you see as the impact of the Inter-
net and unfettered access to health informa-
tion on disease management programs and
the role of the physician?
Almost all of the CMOs perceived that the in-
fluence of the Internet on healthcare is in-
evitable and positive. Most remarkable is the
enormous volume of information that can be
accessed by patients. “It is revolutionary,”
summarized one CMO, representing the gen-
eral feeling of the participants in reaction to the
new reality of patient and consumer empow-
erment. The Internet has become a “driving
force” in this information age. Other respon-
dents replied:
“The Internet will increase patients’ power
with full information.”
“Patients will become more assertive, ed-
ucated and key decision-makers.”
Thus, the CMOs remarked about a gradual
change in the physicians’ role. Physicians are
facing patients armed with large amounts of in-
formation about disease, healthcare, and other
issues for which physicians may not be pre-
pared. Consequently, the physicians’ role in
this new environment should be making sure
that the patient is obtaining quality informa-
tion:
“Physicians will play a large role in pro-
viding accurate evidence based infor-
mation on the Internet.”
“Physicians have to help patients sift
through the information, and assume
more responsibility for the management
of their disease.”
“Physicians will become knowledge bro-
kers rather than just service providers.
If not, they will be pushed to the pe-
riphery.”
In the view of these CMOs, the information age
has also widened the gap between those who
have the financial means to access healthcare
and those who do not. Only a small percentage
of American households have Internet access,
which is directly related to income and is un-
evenly distributed across racial and ethnic
groups.11,12 This greatly biases the distribution
of healthcare information. The CMOs ex-
pressed great concern over this issue.
“The sickest members of our society are
probably on the whole ‘later adapters.’ ”
“Medicaid population is not likely to use
the Internet.”
5. What are some of the concerns regarding pa-
tient confidentiality that will affect disease
management programs?
XU ET AL.22
Great concern was expressed over the confi-
dentialty of patients’ information through the
process of DM. Universally, the CMOs replied
that “there is no confidentiality” in DM pro-
grams, at least not as defined by the traditional
standard of the one-on-one doctor–patient re-
lationship. To integrate the different aspects of
care in DM, patients’ information that was pre-
viously shared only with their own doctors will
now be shared with others. The questions
raised among our respondents were, “Who
owns the data?”, “Will there be legislative over-
sight?”, “Who can access it?”, “under what cir-
cumstances?”, and “for what purpose?”
In spite of these concerns, most CMOs sug-
gested that patient confidentiality is not an is-
sue of DM per se; rather, it is an issue of im-
plementation:
“Patients and physicians will buy into the
program if somehow names could be
blinded.”
“This will depend on implementation.
Systems that permit option and pres-
ence [promoting the] physician and pa-
tient relationship will succeed in com-
plying with confidentiality required.
SUMMARY AND CONCLUSION
This survey, though limited in scope, repre-
sents a good cross-section of the nation’s deci-
sion makers from health systems, hospitals,
and health plans. Similarities among the par-
ticipants in three locations support the gener-
ality of the findings. Answers to several DM-
related questions confirmed literature findings
that there will be greater utilization and influ-
ence of DM in healthcare organizations within
the next 3 years.6 Specifically, CMOs felt that
capitated reimbursement will create the most
successful DM programs because risk will be
shared. In general, CMOs supported a well-de-
fined DM population, balancing cost and qual-
ity, integration of technology, and increased ac-
tion to protect patient confidentiality.
Perhaps the most difficult and challenging
task facing healthcare providers is finding an
optimal balance between short-term DM pro-
gram expenditures and outcome improvement
and long-term cost reductions generated.8 The
CMOs understand that positive ROI is essen-
tial for the DM programs of the future. Many
DM programs, especially those run by man-
aged care organizations, are forced to focus on
diseases and interventions that yield a rapid
ROI. Outcome improvement may become a
secondary issue. This could cause the basic ob-
jectives of DM (i.e., disease prevention and
health promotion) to be neglected.13,14 The
CMOs feel strongly about creating a balance
between cost and outcome improvements.
They do not want to have a “failed” program
because of low quality.
Many segments in healthcare already bene-
fit from the advance of technology. Perhaps the
most noticeable gain is by the patients who,
with an unprecedented access to information,
demand services they have read about on the
Internet. The CMOs, although welcoming the
information age, indicated that providers need
to prepare for changes in the dissemination of
healthcare information. A system that was once
“provider-oriented” healthcare is quickly be-
coming “consumer-focused.”
Almost inevitably, the advancement of tech-
nology raises many issues. Among them is the
security of confidential healthcare information.
This issue becomes more apparent within an
integrated effort, such as a DM progrom, where
sharing of information facilitates data collec-
tion, disease prevention, and health promotion.
All of these aspects are deemed crucial for a
DM program to succeed. To this extent, our re-
spondents agreed and noted that privacy issues
can be overcome without jeopardizing the fun-
damentals of the program.
The CMOs also expressed concerns about so-
cial responsibility. They envisioned a wider
and further disparity that may occur between
the economic stratum because of the advance-
ment of technology and resulting access of in-
formation. This implies that healthcare
providers have some obligations to narrow
these gaps and help those who may not have
the resources needed to access information.
The study results indicate that CMOs hold a
positive view of current developments in DM.
They welcome capitated reimbursement and
the impact of the information age. The confi-
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dence expressed by this national sample of de-
cision makers suggests that despite the pres-
ence of recognized barriers, DM has a secure
role in the future.
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